TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject or subjects legally authorized guardian(s) must provide signed, informed consent prior to performing any trial-related activities~* The subject and his/her guardian(s) must have the ability to comply with the protocol~* The subject must have a confirmed diagnosis of alpha-Mannosidosis as defined by alpha-Mannosidase activity \< 10% of normal activity (historical data)~* The subject must have an age at the time of screening ≥ 5 years and ≤ 35 years~* The subject must have the ability to physically and mentally cooperate in the tests~* The subject must have an ECHO without abnormalities that, in the opinion of the Investigator, would preclude participation in the trial~Exclusion Criteria:~* The subjects diagnosis cannot be confirmed by alpha-Mannosidase activity \< 10% of normal activity~* The subject cannot walk without support~* Presence of known chromosomal abnormality and syndromes affecting psychomotor development, other than alpha-Mannosidosis~* History of BMT~* Presence of known clinically significant cardiovascular, hepatic, pulmonary, or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial~* Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial~* Pregnancy: Pregnant woman is excluded. Before start of the treatment the investigators will for women of childbearing potential perform a pregnancy test and decide whether or not there is a need for contraception~* Psychosis; any psychotic disease, also in remission, is an exclusion criteria~* Planned major surgery that, in the opinion of the Investigator, would preclude participation in the trial~* Participation in other interventional trials testing IMP (including Lamazym) within the last 3 months~* Adult patients who, in the opinion of the Investigator, would be unable to give consent, and who does not have any legal protection or guardianship~* Total IgE \>800 IU/ml~* Known allergy to the IMP or any excipients (Sodium-Phosphate, Glycine, Mannitol)

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Lamazym (Type: ACTIVE_COMPARATOR): 1 mg Lamazym/kg body weight
- Placebo (Type: PLACEBO_COMPARATOR): Placebo is formulated as an isotonic phosphate buffer with glycine and mannitol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients of both sexes, of at least 18 years of age~2. Women of childbearing potential having a reliable contraceptive method~3. Patients undergoing maintenance renal dialysis (MRD), i.e. either haemodialysis or peritoneal dialysis, due to chronic renal failure~4. Patients whose xerosis is related to their renal insufficiency status (uraemic xerosis)~5. Patients suffering from xerosis with a severity score of at least two, on at least one of the five tests areas (right lower leg, left lower leg, forearm with no arterio-venous shunt, chest, dorsum of the neck)~Exclusion Criteria:~1. Patients under 18 years of age~2. Women with childbearing potential having a positive pregnancy test at baseline~3. Patients undergoing renal dialysis for another reason than chronic renal insufficiency~4. Patients whose xerosis is due to another reason than their MRD status~5. Patients suffering from mild xerosis (i.e. score less than two on all the xerotic test areas)~6. Patients with a known history of allergy to one of the ingredients contained in the test product~7. Patients with an intercurrent condition which may interfere with a good conduct or the study parameters of the study~8. Patients treated with any other emollient/moisturising topical preparation within the seven days prior to study entry~9. Patients who participated in a study within the three months prior to study entry~10. Patients who are not affiliated to health insurance~11. Patients who are not able or willing to follow the study instructions -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- V0034CR01B (Type: EXPERIMENTAL): cream
- V0034 CR 01B vehicle (Type: PLACEBO_COMPARATOR): cream

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neurologic Injuries in Adults With Urea Cycle Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria for Participants with OTCD:~* Diagnosis of OTCD or heterozygote state of OTCD by metabolic or molecular means. Female participants must be clinically stable and heterozygous for OTCD. Male participants must be hemizygous for late onset OTCD.~Inclusion Criteria for Healthy Controls:~* No known medical or metabolic disorder~Inclusion Criteria for All Participants:~* IQ of at least 80~* Willing to travel to study site~* English-speaking~* Age between 18 and 60 years~Exclusion Criteria for All Participants:~* Currently being treated for an acute illness~* History of neuropsychiatric drug use~* Unable to undergo MRI scanning without being sedated~* Unable to participate in neurocognitive and/or motor testing~* Metal device in body that might interfere with MRI scanning~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: None): Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD
- 2 (Type: None): Healthy males or females without known medical or metabolic disorder (control group)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine Versus Placebo in Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male/Female outpatients 18 years of age with chronic low back pain~* Females of child bearing potential must test negative on a pregnancy test at visit 1.~Exclusion Criteria:~* Have a serious or unstable diseases of the heart or blood vessels, liver, kidney, lungs, or blood-related illness~* Problems with decreased blood flow to arms and legs (peripheral vascular disease), or other medical conditions~* Psychiatric conditions that, in the opinion of the investigator, would affect your participation or be likely to lead to hospitalization during the course of the study~* Have acute liver injury (such as hepatitis) or severe cirrhosis~* Have had previous exposure to duloxetine~* Have a body mass index (BMI) over 40~* Have a major depressive disorder~* Require daily narcotics~* Have suicidal risk~* Have a presence of any factors/conditions, medical or other, that in the judgment of the investigator may interfere with performance of study outcome measures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duloxetine (Type: EXPERIMENTAL): 30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
- Placebo (Type: PLACEBO_COMPARATOR): every day (QD), by mouth (PO), 13 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 14.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary open-angle glaucoma (including pigmentary or pseudoexfoliative) or ocular hypertension in 1 or both eyes.~* Qualifying intraocular pressure (IOP) in the same eye at the Eligibility 1 and 2 measurements.~Exclusion Criteria:~* Closed/barely open anterior chamber angle or a history of acute angle closure in either eye.~* Anticipate the need to initiate or modify medication (systemic or topical) that is known to affect intraocular pressure (IOP) during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stage 1: PF-04217329 - Lowest Dose (Type: EXPERIMENTAL): None
- Stage 1: PF-04217329 - Low Dose (Type: EXPERIMENTAL): None
- Stage 1: PF-04217329 - Middle Dose (Type: EXPERIMENTAL): None
- Stage 1: PF-04217329 - High Middle Dose (Type: EXPERIMENTAL): None
- Stage 1: PF-04217329 - High Dose (Type: EXPERIMENTAL): None
- Stage 1: PF-02417329 - Highest Dose (Type: EXPERIMENTAL): None
- Stage 1: PF-04217329 - Vehicle (Type: EXPERIMENTAL): None
- Stage 2: PF-04217329 - Low Dose + Latanoprost Vehicle (Type: EXPERIMENTAL): None
- Stage 2: PF-04217329 - Middle Dose + Latanoprost Vehicle (Type: EXPERIMENTAL): None
- Stage 2: PF-04217329 - High Dose + Latanoprost Vehicle (Type: EXPERIMENTAL): None
- Stage 2: PF-04217329 - Low Dose + Latanoprost 0.005% (Type: EXPERIMENTAL): None
- Stage 2: PF-04217329 - Middle Dose + Latanoprost 0.005% (Type: EXPERIMENTAL): None
- Stage 2: PF-04217329 - High Dose + Latanoprost 0.005% (Type: EXPERIMENTAL): None
- Stage 2: PF-04217329 - Vehicle + Latanoprost 0.005% (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Severe Haemophilia A (FVIII:C \< 1%)~* Male patients \>= 18 years of age~* Previous treatment with a FVIII concentrate for at least 150 EDs~* Good documentation regarding dosing and bleeding frequency in the 6 months preceding study start~* Immunocompetence (CD4+ count \> 200/uL)~Exclusion Criteria:~* Any coagulation disorder other than Haemophilia A~* Present of past FVIII inhibitor activity~* Severe liver or kidney disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Human-cl rhFVIII (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PTG-300 in Subjects With Hereditary Hemochromatosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 18 and older~* Confirmed diagnosis of HFE-related hereditary hemochromatosis with prior genotype testing~* Documented stable phlebotomy for ≥ 6 months~* Screening hemoglobin \>11.5 g/dL~* Documented evidence of prior serum ferritin ≥500 ng/mL~* Serum ferritin \>50 ng/mL and \<300 ng/mL at screening~Exclusion Criteria:~* Clinically meaningful laboratory abnormality~* Receiving iron chelation therapy~* Receiving erythrocytapheresis~* Pregnant or lactating females~* Infection requiring hospitalization or intravenous antimicrobial therapy, or opportunistic infection within 3 months of dosing; any infections requiring antimicrobial therapy within 4 weeks of dosing.~* Serious or unstable medical or psychiatric condition that would prevent subject providing informed consent~* Organ damage from iron overload~* Primary or secondary immunodeficiency~* Positive hepatitis B or hepatitis C or known human immunodeficiency virus infection~* Known history of autoimmune/inflammatory diseases~* Any surgical procedures requiring general anesthesia within 1 month prior to screening or planned surgery during study~* History of invasive malignancies within last 2 years, except non-malignant skin cancer and local cured prostate cancer, cervical cancer, or ductal carcinoma in situ~* Receipt of an investigational agent within 30 days of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PTG-300 (Type: EXPERIMENTAL): PTG-300 Subcutaneous

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Green Tea Extract (Polyphenon E®)in Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male or female with mildly to moderately active ulcerative colitis~Exclusion Criteria:~* Off prohibited medications for proscribed period of time~* Evidence of infectious colitis~* Labs outside of range~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Polyphenon E treatment (Type: EXPERIMENTAL): Polyphenon E® therapy was given for 56 days.
- Placebo (Type: PLACEBO_COMPARATOR): Oral Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who had been diagnosed with iNHL that had progressed.~* Participants must have exhibited lack of CR or progressive disease (PR) or progression within 6 months after the last dose of a chemotherapy induction regimen or RIT.~* Participants must have had rituximab-refractory disease, defined as lack of CR or PR or PD within 6 months of last dose.~* Measurable disease with a lymph node or tumor mass ≥1.5 centimeters in at least one dimension by computed tomography (CT), positron emission tomography/CT or magnetic resonance imaging.~* Adequate renal and hepatic function.~Exclusion Criteria:~* Candidate for potentially curative therapies in the opinion of the investigator.~* Previous treatment with a PI3K inhibitor or Bruton's tyrosine kinase inhibitor.~* Prior history of allogeneic hematopoietic stem cell transplant.~* Prior chemotherapy, cancer immunosuppressive therapy, or other investigational agents within 4 weeks before first dose of study drug.~* Grade 3B FL and/or clinical evidence of transformation to a more aggressive subtype of lymphoma.~* Symptomatic central nervous system NHL.~* Ongoing systemic bacterial, fungal, or viral infections at the time of initiation of study treatment.~* Prior, current, or chronic hepatitis B or hepatitis C infection, positive result for hepatitis C virus antibodies, hepatitis B surface antigen, or hepatitis B core antibodies.~* History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months prior to first dose of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duvelisib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Dexmedetomidine, Dexamethasone and Interscalene Block Duration After Arthroscopic Shoulder Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Elective ambulatory surgery patients undergoing arthroscopic shoulder surgery~* Including rotator cuff repair~* Stabilization procedures~* Acromioplasty~* Debridement and distal clavicle excision~Exclusion Criteria:~* Patient refusal~* Diabetes~* Pregnancy~* Coagulopathy significant enough to be a contraindication to regional anesthesia as determined by the attending anesthesiologist~* Sensitivity to local anesthetics, dexamethasone or dexmedetomidine~* Severe chronic obstructive pulmonary disease~* Contralateral vocal cord paralysis~* Contralateral diaphragmatic paralysis~* Surgical limb brachial plexus neuropathy~* Interscalene block site infection~* Systemic glucocorticoids in the last 2 weeks~* Epidural or intraarticular steroid injection in the past 3 months~* Chronic opioid use defined as daily use for the last two weeks~* Active peptic ulcer disease~* End-stage renal disease~* Cirrhotic liver disease~* Ventricular dysfunction~* Advanced heart block~* Previous participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: ACTIVE_COMPARATOR): 4 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
- Dexmedetomidine (Type: ACTIVE_COMPARATOR): 50 micrograms dexmedetomidine administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
- Dexamethasone and Dexmedetomidine (Type: ACTIVE_COMPARATOR): 4 milligrams dexamethasone and 50 micrograms dexmedetomidine administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Parental or sibling history of asthma.~2. Child must be less than 24 months of age.~3. Presence of viral upper or lower respiratory tract symptoms.~Exclusion Criteria:~1. History of recurrent wheezing requiring systemic corticosteroids.~2. Prior history of lung disease.~3. Birth \< 36 weeks gestation.~4. Immunodeficiency~5. Treatment with ribavirin, systemic or inhaled corticosteroids during the RSV infection.~6. Congenital heart disease.~7. No history of parental or sibling asthma.~8. Less than 48 hour or more than 5 day duration of viral URI symptoms since the peak symptoms from RSV would be expected to occur from 2-5 days into course of infection.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Months
- Healthy Volunteers: t

Study Arms:
- Toll-like Receptor 4 -2026/GG Genotype (Type: None): Toll-like Receptor 4 (TLR4) -2026/GG Genotype of interest hypothesized to be associated with less inflammation during Respiratory Syncytial virus (RSV) infection
- Toll-like Receptor 4 -2026/AG and AA Genotypes (Type: None): Toll-like Receptor 4 (TLR4) -2026/AG and AA control genotypes hypothesized to be associated with more inflammation during respiratory syncytial virus (RSV) infection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete